Treatment of Orthostatic Intolerance
Study Details
Study Description
Brief Summary
This trial is designed to study the effects of various mechanistically unique medications in controlling excessive increases in heart rate with standing and in improving the symptoms of orthostatic intolerance in patients with this disorder.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 1/Phase 2 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: 1 Acetazolamide |
Drug: Acetazolamide
250 mg PO x 1
Other Names:
|
Experimental: 2 Atomoxetine |
Drug: Atomoxetine
10-40 mg PO x 1 dose
Other Names:
Drug: Atomoxetine & Propranolol
Atomoxetine 10-40 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose
Other Names:
|
Experimental: 3 NO Drug |
Other: NO Drug
No intervention - just monitoring
|
Experimental: 4 Clonidine |
Drug: Clonidine
Clonidine 0.05-0.3 mg PO x 1 dose
Other Names:
|
Experimental: 5 Entacapone |
Drug: Entacapone
Entacapone 200-400 mg PO x 1 dose
Other Names:
Drug: Entacapone & Propranolol
Entacapone 200-400 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose
Other Names:
|
Experimental: 6 Indomethacin |
Drug: Indomethacin
Indomethacin 25-50 mg PO x 1 dose
Other Names:
|
Experimental: 7 Isosorbide Dinitrate |
Drug: Isosorbide Dinitrate
Isosorbide dinitrate 5-20 mg PO x 1 dose
Other Names:
|
Experimental: 8 Mecamylamine |
Drug: Mecamylamine
mecamylamine 1.25-5 mg PO x 1 dose
Other Names:
|
Experimental: 9 Memantine |
Drug: memantine
memantine 5-20 mg PO x 1 dose
Other Names:
|
Experimental: 10 Melatonin |
Dietary Supplement: Melatonin
melatonin 3 mg PO x 1 dose
|
Experimental: 11 Midodrine |
Drug: Midodrine
midodrine 2.5-10 mg PO x 1 dose
Other Names:
|
Experimental: 12 Modafinil |
Drug: Modafinil
modafinil 100-200 mg PO x 1 dose
Other Names:
Drug: Modafinil & Propranolol
Modafinil 100-200 mg PO x 1 dose AND Propranolol 20 mg PO x 1 dose
Other Names:
|
Experimental: 13 Octreotide |
Drug: Octreotide
octreotide 12.5-50 mcg Subcutaneous x 1 dose
Other Names:
|
Placebo Comparator: 14 Placebo (lactose tablet) |
Radiation: Placebo
lactose tablet x 1 pill
|
Experimental: 15 Propranolol |
Drug: Entacapone & Propranolol
Entacapone 200-400 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose
Other Names:
Drug: Atomoxetine & Propranolol
Atomoxetine 10-40 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose
Other Names:
Drug: Propranolol
Propranolol 10-80 mg PO x 1-2 dose
Other Names:
Drug: Modafinil & Propranolol
Modafinil 100-200 mg PO x 1 dose AND Propranolol 20 mg PO x 1 dose
Other Names:
|
Experimental: 16 Sertraline |
Drug: Sertraline
sertraline 25-50 mg PO x 1 dose
Other Names:
|
Experimental: 17 Normal Saline (0.9%) 1 liter |
Procedure: IV Saline
1 liter IV over 2 hours
Other Names:
|
Experimental: 18 Drinking Water |
Other: Drinking Water
16 fluid ounces
|
Experimental: 19 Dead Space Breathing Device |
Device: Breathing Device
Breathing through a dead space tube
|
Experimental: Abdominal Binder Abdominal binder with inflatable pressure over abdomen |
Device: Abdominal binder
Using large blood pressure cuffs linked together, they are wrapped around the subjects abdomen and inflated to generate increased pressure to below tolerably threshold.
|
Outcome Measures
Primary Outcome Measures
- Increase in heart rate with standing [1-4 hours]
Secondary Outcome Measures
- Sitting heart rate [1-4 hours]
- Standing heart rate [1-4 hours]
- Blood pressure [1-4 hours]
- Decrease in blood pressure with standing [1-4 hours]
- Orthostatic symptoms score [Baseline, 2h, 4h]
Eligibility Criteria
Criteria
Inclusion Criteria:
- Chronic symptoms (> 6 months) with standing upright
Exclusion Criteria:
-
Obvious cause of hypovolemia or drugs that could worsen tachycardia
-
Chronic severe medical conditions such as cancer or ischemic heart disease
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Vanderbilt University Autonomic Dysfunction Center | Nashville | Tennessee | United States | 37232-2195 |
Sponsors and Collaborators
- Satish R. Raj
- National Institutes of Health (NIH)
Investigators
- Principal Investigator: Satish R Raj, MD MSCI, Vanderbilt University School of Medicine
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 008397
- UL1TR000445